NYSE:JNJPharmaceuticals
Assessing Johnson & Johnson (JNJ) Valuation After Earnings Beat Guidance Hike And Ongoing Dividend Growth
Johnson & Johnson (JNJ) just reported quarterly earnings and sales ahead of expectations, supported by both its Innovative Medicines and MedTech segments, while raising 2026 guidance and extending its dividend growth streak to 64 years.
See our latest analysis for Johnson & Johnson.
Despite the earnings beat and steady dividend record, the stock is trading at US$226.71, with the share price down 5.01% over 30 days and 6.88% over 90 days. The 1-year total shareholder return of 53.99% and...